Arrowhead Pharmaceuticals Net Income Over Time
| ARWR Stock | USD 63.83 0.01 0.02% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Arrowhead Pharmaceuticals Performance and Arrowhead Pharmaceuticals Correlation. Arrowhead | Build AI portfolio with Arrowhead Stock |
Can Biotechnology industry sustain growth momentum? Does Arrowhead have expansion opportunities? Factors like these will boost the valuation of Arrowhead Pharmaceuticals. If investors know Arrowhead will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Arrowhead Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth 0.098 | Earnings Share 1.6 | Revenue Per Share | Quarterly Revenue Growth 104.613 | Return On Assets |
Investors evaluate Arrowhead Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Arrowhead Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Arrowhead Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Arrowhead Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Arrowhead Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Arrowhead Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Arrowhead Pharmaceuticals and related stocks such as Vaxcyte, Crispr Therapeutics, and PTC Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCVX | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (29.5 M) | (50.3 M) | (89.2 M) | (100.1 M) | (223.5 M) | (402.3 M) | (463.9 M) | (417.5 M) | (396.7 M) |
| CRSP | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (25.8 M) | (23.2 M) | (68.4 M) | (165 M) | 66.9 M | (348.9 M) | 377.7 M | (650.2 M) | (153.6 M) | (366.3 M) | (581.6 M) | (552.5 M) |
| PTCT | 30.9 M | 30.9 M | (26.2 M) | (51.6 M) | (93.8 M) | (170.4 M) | (142.1 M) | (79 M) | (128.1 M) | (251.6 M) | (438.2 M) | (523.9 M) | (559 M) | (626.6 M) | (363.3 M) | (327 M) | (343.3 M) |
| ACLX | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (18 M) | (32.1 M) | (63.9 M) | (188.7 M) | (70.7 M) | (107.3 M) | (96.6 M) | (101.4 M) |
| KRYS | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (7.9 M) | (10.9 M) | (19.1 M) | (32.2 M) | (69.6 M) | (140 M) | 10.9 M | 89.2 M | 102.5 M | 107.7 M |
| TGTX | (3.6 M) | (853.1 K) | (18.1 M) | (20.5 M) | (55.8 M) | (62.9 M) | (78.3 M) | (118.5 M) | (173.5 M) | (172.9 M) | (279.4 M) | (348.1 M) | (223.8 M) | 12.7 M | 23.4 M | 21 M | 22.1 M |
| ALKS | (40.1 M) | 25 M | 25 M | 17.6 M | (30.1 M) | (227.2 M) | (208.4 M) | (157.9 M) | (139.3 M) | (196.6 M) | (110.9 M) | (48.2 M) | (158.3 M) | 355.8 M | 367.1 M | 422.1 M | 443.2 M |
| AXSM | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (6 M) | (12.2 M) | (27.2 M) | (28.9 M) | (31 M) | (68.3 M) | (102.9 M) | (134.9 M) | (187.1 M) | (239.2 M) | (287.2 M) | (258.5 M) | (245.6 M) |
| KYMR | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (41.3 M) | (45.6 M) | (100.2 M) | (154.8 M) | (147 M) | (223.9 M) | (201.5 M) | (191.4 M) |
Arrowhead Pharmaceuticals and related stocks such as Vaxcyte, Crispr Therapeutics, and PTC Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Arrowhead Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Arrowhead Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Arrowhead Pharmaceuticals | ARWR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 177 East Colorado |
| Exchange | NASDAQ Exchange |
USD 63.83
Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.